Literature DB >> 18410901

Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases.

Naoyuki Uchida1, Atsushi Wake, Shinsuke Takagi, Hisashi Yamamoto, Daisuke Kato, Yoshiko Matsuhashi, Tomoko Matsumura, Sachiko Seo, Naofumi Matsuno, Kazuhiro Masuoka, Eiji Kusumi, Koichiro Yuji, Shigesaburo Miyakoshi, Michio Matsuzaki, Akiko Yoneyama, Shuichi Taniguchi.   

Abstract

Although allogeneic hematopoietic stem cell transplantation is a potentially curative approach for advanced hematologic diseases, its application to elderly people is limited because of their comorbid physical conditions and lower chance of finding suitable related donors. Umbilical cord blood transplantation with reduced-intensity pretransplant conditioning (RI-UCBT) is 1 way to avoid these obstacles. We analyzed elderly patients aged 55 years and older with hematologic diseases who underwent RI-UCBT at our institute to assess feasibility and effectiveness of this treatment approach. Among the 70 patients included, 50 died, 74% of them from nonrelapse causes. Infection was the primary cause of death. Estimated overall survival and progression-free survival at 2 years were both 23%. In multivariate analyses, standard-risk diseases, age younger than 61 years, grade 0-II acute graft-versus-host disease, and the absence of preengraftment immune reaction were significantly associated with better overall survival. RI-UCBT is a potentially curative and applicable approach for elderly patients. Higher mortality, especially from nonrelapse causes, is the biggest problem to be solved to increase the feasibility of this approach.

Entities:  

Mesh:

Year:  2008        PMID: 18410901     DOI: 10.1016/j.bbmt.2008.03.003

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  25 in total

Review 1.  Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.

Authors:  Kentaro Minagawa; Motohiro Yamamori; Yoshio Katayama; Toshimitsu Matsui
Journal:  Int J Hematol       Date:  2012-05-17       Impact factor: 2.490

2.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Authors:  Claudio G Brunstein; Ephraim J Fuchs; Shelly L Carter; Chatchada Karanes; Luciano J Costa; Juan Wu; Steven M Devine; John R Wingard; Omar S Aljitawi; Corey S Cutler; Madan H Jagasia; Karen K Ballen; Mary Eapen; Paul V O'Donnell
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

3.  I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.

Authors:  H Yamamoto; N Uchida; N Matsuno; A Kon; A Nishida; H Ota; T Ikebe; N Nakano; K Ishiwata; H Araoka; S Takagi; M Tsuji; Y Asano-Mori; G Yamamoto; K Izutsu; K Masuoka; A Wake; A Yoneyama; S Makino; S Taniguchi
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

4.  Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single institute.

Authors:  Takayuki Nakamura; Eijiro Oku; Kei Nomura; Satoshi Morishige; Yuka Takata; Ritsuko Seki; Rie Imamura; Koichi Osaki; Michitoshi Hashiguchi; Kazuaki Yakushiji; Fumihiko Mouri; Shinichi Mizuno; Koji Yoshimoto; Koichi Ohshima; Koji Nagafuji; Takashi Okamura
Journal:  Int J Hematol       Date:  2012-09-14       Impact factor: 2.490

5.  Feasibility of umbilical cord blood transplantation with a myeloablative, reduced toxicity-conditioning regimen.

Authors:  M Nishimoto; H Nakamae; M Nakamae; A Hirose; K Hagihara; H Koh; T Nakane; Y Terada; M Hino
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

6.  Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation.

Authors:  Masahiko Sumi; Ikuo Shimizu; Keijiro Sato; Toshimitsu Ueki; Daigo Akahane; Mayumi Ueno; Naoaki Ichikawa; Shinji Nakao; Hikaru Kobayashi
Journal:  Int J Hematol       Date:  2010-11-05       Impact factor: 2.490

7.  Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.

Authors:  Daniel Weisdorf; Mary Eapen; Annalisa Ruggeri; Mei-Jie Zhang; Xiaobo Zhong; Claudio Brunstein; Celalettin Ustun; Vanderson Rocha; Eliane Gluckman
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-26       Impact factor: 5.742

8.  Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.

Authors:  Masamichi Isobe; Takaaki Konuma; Masayoshi Masuko; Naoyuki Uchida; Shigesaburo Miyakoshi; Yasuhiro Sugio; Shuro Yoshida; Masatsugu Tanaka; Yoshiko Matsuhashi; Norimichi Hattori; Makoto Onizuka; Nobuyuki Aotsuka; Yasushi Kouzai; Atsushi Wake; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Journal:  Ann Hematol       Date:  2021-02-23       Impact factor: 3.673

9.  Characteristics of chronic GVHD after cord blood transplantation.

Authors:  L F Newell; M E D Flowers; T A Gooley; F Milano; P A Carpenter; P J Martin; C Delaney
Journal:  Bone Marrow Transplant       Date:  2013-04-15       Impact factor: 5.483

10.  Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.

Authors:  F Ostronoff; F Milano; T Gooley; J A Gutman; P McSweeney; F B Petersen; B M Sandmaier; R Storb; C Delaney
Journal:  Bone Marrow Transplant       Date:  2012-12-17       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.